Platelet and Coagulation Function in Patients with Abnormal Cardiac Valves Treated with Sulphinpyrazone

Summary

Eight patients on warfarin with rheumatic heart disease and prosthetic cardiac valves were selected for study on the basis of persistently elevated plasma β-thromboglobulin (β-tg) and platelet factor 4 (PF4) concentrations. Platelet mean lifespan and fibrinogen half life were short, and positively correlated, and both were inversely related to the Plasma concentrations of the platelet specific proteins. Antithrombin III (ATIII) levels were also reduced. Treatment with sulphinpyrazone resulted in lengthening of both platelet and fibrinogen survival, a rise in ATIII but no change in the βtg or PF4 concentrations. It is concluded that patients with abnormal cardiac valves and raised plasma levels of βtg or PF4 have, despite warfarin, a consumption coagulopathy that can be inhibited by sulphinpyrazone.

Keywords

Abnormal cardiac valves - β-thromboglobulin - Platelet factor 4 - Platelet survival - Fibrinogen survival - Antithrombin III - Sulphinpyrazone

• References

• 1 Coulshed N, Epstein EJ, McKendrick CS, Galloway RW, Walker E. Systemic embolism in mitral valve disease. Br Heart J 1970; 32: 26-34
• 2 Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. Br Med J 1964; 1: 1209-1212
• 3 Fleming HA, Bailey SM. Mitral valve disease, systemic embolism and anticoagulants. Postgrad Med J 1971; 47: 599-604
• 4 Smythe HA, Ogryzlo MA, Murphy EA, Mustard JF. The effect of sulphinpyrazone (Anturan) on platelet economy and blood coagulation in man. Can Med Assoc J 1965; 92: 818-821
• 5 Weily HS, Steele PP, Davies H, Pappas G, Genton E. Platelet survival in patients with substitute heart valves. N Engl J Med 1974; 290: 534-537
• 6 Steele PP, Weily HS, Davies H, Genton E. Platelet survival in patients with rheumatic heart disease. N Engl J Med 1974; 290: 537-539
• 7 Ludlam CA, Moore S, Bolton AE, Pepper DS, Cash JD. The release of a human platelet specific protein measured by a radioimmunoassay. Thromb Res 1975; 6: 543-548
• 8 Bolton AE, Ludlam CA, Pepper DS, Moore S, Cash JD. A radioimmunoassay for platelet factor 4. Thromb Res 1976; 8: 51-58
• 9 Doyle DJ, Chesterman CN, Cade JF, McGready JR, Rennie SC, Morgan FJ. Plasma concentrations of platelet specific proteins correlated with platelet survival. Blood 1980; 55: 82-84
• 10 Cella G, Lane DA, Kakkar VV, Donuto A, Volta DS. Plasma β-thromboglobulin and platelet factor 4 levels in cardiac valve replacements. Thromb Haemostas 1979; 42: 134
• 11 Ludlam CA. Evidence for the platelet specificity or β P-thromboglobulin and studies on its plasma concentration in healthy individuals. Br J Haematol 1979; 41: 271-278
• 12 Ludlam CA, Allen N, Blandford RB, Dowdle R, Bentley N, Bloom AL. β-thromboglobulin and platelet survival in patients with rheumatic heart disease and prosthetic cardiac valves and their treatment with sulphinpyrazone. Thromb Haemostas 1979; 42: 329
• 13 Weily HS, Genton E. Altered platelet function in patients with prosthetic mitral valves. Effects of sulphinpyrazone therapy Circulation 1970; 42: 967-972
• 14 Wiley JS, Chesterman CN, Morgan FJ, Castaldi PA. The effect of sulphinpyrazone on the aggregation and release reactions of human platelets. Thromb Res 1979; 14: 23-33
• 15 Ludlam CA, Cash JD. Studies on the liberation of β-thromboglobulin from human platelets in vitro. Br J Haematol 1976; 33: 239-247
• 16 Bolton AE, Ludlam CA, Moore S, Pepper DS, Cash JD. Three approaches to the radioimmunoassay of human β-thromboglobuhn. Br J Haematol 1976; 33: 233-238
• 17 Aster RH, Jandl JH. Platelet sequestration in man. J Clin Invest 1964; 43: 843-855
• 18 Harker CA, Finch CA. Thrombokinetics in man. J Clin Invest 1969; 48: 963-974
• 19 Murphy EA, Francis ME. The estimation of blood platelet survival. II The Multiple Hit Model Thrombos Diathes Haemorrh 1971; 25: 53-80
• 20 Ratnoff OD, Menzie C. A new method for the determination of fibrinogen in small samples of plasma. J Haematol Clin Med 1951; 37: 316
• 21 Regoeczi E. Iodine-labelled fibrinogen: A review. Br J Haematol 1971; 20: 649-663
• 22 Bradley J. Behaviour of commercially prepared 1-125 fibrinogen in metabolic studies. J Clin Path 1975; 28: 478-493
• 23 Stegel S. Non-parametric statistics for the behavioural sciences. McGraw-Hill Kogukudia; Tokyo: 1956
• 24 Pumphrey CW, Dawes J. Elevation of plasma β-thromboglobulin in patients with prosthetic cardiac valves. Thromb Res 1981; 27: 147-156
• 25 Ludlam CA, Bolton AE, Moore S, Cash JD. New rapid method for diagnosis of deep venous thrombosis. Lancet 1975; 2: 259-260
• 26 Ludlam CA, Cash JD. β-thromboglobulin.A new tool for the diagnosis of hypercoagulability. In Haemostasis and Thrombosis Ed Neri Semeri GG. Prentice CRM 1979; 159-168
• 27 Harker LA, Slichter SJ. Arterial and venous thromboembolism kinetic characterisation and evaluation of therapy. Thrombos Diathes Haemorrh 1974; 31: 188-203
• 28 Harker LA, Slichter SJ. Platelet and fibrinogen consumption in man. N Engl J Med 1972; 287: 999-1005
• 29 Woods HF, Ash G, Weston MJ. Sulphinpyrazone reduces deposition of fibrin on dialyser membranes. Thromb Haemostas 1979; 42: 401
• 30 Hoogendijk EM, ten CateJ, Ludlam CA, Bruin T. No effect of aspirin on p-thromboglobulin plasma levels in healthy volunteers. Thromb Res 1980; 19: 257-262
• 31 Boughton BJ, Allington MJ, King A. Platelet and plasma β- thromboglobulin in myeloproliferative syndromes and secondary polycythaemia. Br J Haematol 1978; 40: 125-142
• 32 Steele P, Rainwater J. Favourable effect of sulphinpyrazone on thromboembolism in patients with rheumatic heart disease. Circulation 1980; 62: 462-465